Your browser doesn't support javascript.
loading
A guide to senolytic intervention in neurodegenerative disease.
Lee, Suckwon; Wang, Ellen Y; Steinberg, Alexandra B; Walton, Chaska C; Chinta, Shankar J; Andersen, Julie K.
Afiliação
  • Lee S; Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA, 94945, USA.
  • Wang EY; Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA, 94945, USA.
  • Steinberg AB; University of Wisconsin Department of Biochemistry, 433 Babcock Drive., Madison, WI, 53706, USA.
  • Walton CC; Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA, 94945, USA. Electronic address: CWalton@buckinstitute.org.
  • Chinta SJ; Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA, 94945, USA; Touro University California, College of Pharmacy, 1310 Club Dr., Vallejo, CA, 94592, USA. Electronic address: schinta@touro.edu.
  • Andersen JK; Buck Institute for Research on Aging, 8001 Redwood Blvd., Novato, CA, 94945, USA. Electronic address: jandersen@buckinstitute.org.
Mech Ageing Dev ; 200: 111585, 2021 12.
Article em En | MEDLINE | ID: mdl-34627838
ABSTRACT
Cellular senescence is a potential tumor-suppressive mechanism that generally results in an irreversible cell cycle arrest. Senescent cells accumulate with age and actively secrete soluble factors, collectively termed the 'senescence-associated secretory phenotype' (SASP), which has both beneficial and detrimental effects. Although the contribution of senescent cells to age-related pathologies has been well-established outside the brain, emerging evidence indicates that brain cells also undergo cellular senescence and contribute to neuronal loss in the context of age-related neurodegenerative diseases. Contribution of senescent cells in the pathogenesis of neurological disorders has led to the possibility of eliminating senescence cells via pharmacological compounds called senolytics. Recently several senolytics have been demonstrated to elicit improved cognitive performance and healthspan in mouse models of neurodegeneration. However, their translation for use in the clinic still holds several potential challenges. This review summarizes available senolytics, their purported mode of action, and possible off-target effects. We also discuss possible alternative strategies that may help minimize potential side-effects associated with the senolytics approach.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Envelhecimento / Senescência Celular / Doenças Neurodegenerativas / Senoterapia Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Envelhecimento / Senescência Celular / Doenças Neurodegenerativas / Senoterapia Idioma: En Ano de publicação: 2021 Tipo de documento: Article